Distinguished in Neurofibromatosis Type 1 (NF1)

Dr. Roger Packer

Neurology | Pediatrics

111 Michigan Ave Nw,

Washington, DC

Distinguished in Neurofibromatosis Type 1 (NF1)

111 Michigan Ave Nw,

Washington, DC

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Roger Packer is a Neurologist and a Pediatrics provider in Washington, Washington, D.c.. Dr. Packer is rated as a Distinguished provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Brain Tumor, Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, and Gliomatosis Cerebri.

His clinical research consists of co-authoring 255 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 44 articles and participated in 3 clinical trials in the study of Neurofibromatosis Type 1 (NF1).

Specialties

Neurology

Pediatrics

Licenses

Psychiatry & Neurology in DC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Humana

HMO
INDEMNITY
POS
PPO

Locations

111 Michigan Ave Nw, Washington, DC 20010

Call: 202-884-2610

Additional Areas of Focus

Dr. Packer has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma

Enrollment Status: Active_not_recruiting

Publish Date: September 29, 2025

Intervention Type: Biological

Study Drug: APX005M

Study Phase: Phase 1

Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Enrollment Status: Completed

Publish Date: August 27, 2025

Intervention Type: Drug

Study Drug: Crizotinib

Study Phase: Phase 2

Pediatric Neuro-Oncology Consortium (PNOC)-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors

Enrollment Status: Completed

Publish Date: August 03, 2025

Intervention Type: Drug

Study Drug: Vemurafenib

Study Phase: Early Phase 1

A Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors (NF112)

Enrollment Status: Not_yet_recruiting

Publish Date: June 08, 2025

Intervention Type: Drug

Study Drug: Selumetinib

Study Phase: Phase 2

A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)

Enrollment Status: Completed

Publish Date: May 02, 2025

Intervention Type: Drug

Study Drug: Binimetinib

Study Phase: Phase 2

A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1

Enrollment Status: Terminated

Publish Date: March 21, 2025

Intervention Type: Drug

Study Drug: Poly ICLC

Study Phase: Phase 2

A Phase 2 Dose-escalation Study Examining the Safety, Pharmacokinetics, and Preliminary Efficacy of Ascending Drug and Energy Dose Combinations for Sonodynamic Therapy Using SONALA-001 in Combination with Exablate 4000 Type 2.0 MR-Guided Focused Ultrasound in Subjects with Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)

Enrollment Status: Suspended

Publish Date: September 19, 2024

Intervention Type: Combination product

Study Drug: SONALA-001+MR-Guided Focused Ultrasound device

Study Phase: Phase 2

Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma

Enrollment Status: Completed

Publish Date: April 25, 2024

Intervention Type: Drug

Study Drug: LBH589

Study Phase: Phase 1

Development of Stem Cell Lines in Children With Neurofibromatosis Type 1 and Tumors of the Central Nervous System

Enrollment Status: Withdrawn

Publish Date: February 07, 2024

Intervention Type: Diagnostic test

Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)

Enrollment Status: Completed

Publish Date: December 13, 2023

Intervention Type: Drug

Study Drugs: Dabrafenib, Trametinib, Carboplatin with Vincristine

Study Phase: Phase 2

Frameshift Peptides of Children With Neurofibromatosis Type 1 (NF1) and Either Low-Grade Gliomas or Plexiform Neurofibromas

Enrollment Status: Completed

Publish Date: August 31, 2022

Intervention Type: Genetic

A Study of INFUSE Bone Graft (Recombinant Human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis 1 (NF1)

Enrollment Status: Terminated

Publish Date: October 27, 2021

Intervention Type: Procedure, Device

Study Phase: Not Applicable

Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors

Enrollment Status: Terminated

Publish Date: March 02, 2021

Intervention Type: Other, Drug

Study Phase: Phase 1

Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma

Enrollment Status: Terminated

Publish Date: February 24, 2020

Intervention Type: Other, Biological

Study Phase: Phase 2

View 13 Less Clinical Trials

260 Total Publications

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.

Journal: Nature medicine

Published: April 16, 2025

View All 260 Publications

Similar Doctors

Elite in Neurofibromatosis Type 1 (NF1)

Dr. Jaishri Blakeley

Neurology

Elite in Neurofibromatosis Type 1 (NF1)

Dr. Jaishri Blakeley

Neurology

Johns Hopkins University

601 N Caroline St,

Baltimore, MD

(34.1 miles away)

410-955-5080

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Jaishri Blakeley is a Neurologist in Baltimore, Maryland. Dr. Blakeley is rated as an Elite provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). Her top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy.

Elite in Neurofibromatosis Type 1 (NF1)

Dr. Carlos Romo

Neurology

Elite in Neurofibromatosis Type 1 (NF1)

Dr. Carlos Romo

Neurology

Johns Hopkins University

600 N Wolfe St, Blalock 266,

Baltimore, MD

(34.2 miles away)

410-502-4340

Languages Spoken:

English

See accepted insurances

Carlos Romo is a Neurologist in Baltimore, Maryland. Dr. Romo is rated as a Distinguished provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Schwannomatosis, and Astrocytoma.

Distinguished in Neurofibromatosis Type 1 (NF1)

Dr. Srivandana Akshintala

Pediatrics

Distinguished in Neurofibromatosis Type 1 (NF1)

Dr. Srivandana Akshintala

Pediatrics

111 Michigan Ave Nw, Dept Of Hematology/oncology,

Washington, DC

(0.1 miles away)

202-476-2800

Languages Spoken:

English

See accepted insurances

Srivandana Akshintala is a Pediatrics provider in Washington, Washington, D.c.. Dr. Akshintala is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). Her top areas of expertise are Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Neuroendocrine Tumor, Ectodermal Dysplasias, and Thyroidectomy.

VIEW MORE NEUROFIBROMATOSIS TYPE 1 (NF1) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Packer's expertise for a condition

ConditionClose